ENTRY       D08946                      Drug
NAME        Mipomersen sodium (USAN);
            Kynamro (TN)
FORMULA     C230H305N67Na19O122P19S19
EXACT_MASS  7589.7486
MOL_WEIGHT  7594.8005
SEQUENCE    
            5'-mG-mC*-mC*-mU*-mC*-dA-dG-dT-dC*-dT-dG-dC*-dT-dT-dC*-mG-mC*-mA-mC*-mC*-3'
            2'-O-(2-methoxyethyl) nucleoside (m) and 2'-deoxynucleoside (d)
            with  methyl  group  at  position  5 of  C  and  U  (*)
  TYPE      Nucleotide
REMARK      ATC code: C10AX11
EFFICACY    Antihyperlipidemic, Apolipoprotein B production inhibitor
  DISEASE   Homozygous familial hypercholesterolemia [DS:H00155]
  TYPE      Antisense oligonucleotide
COMMENT     Treatment of hypercholesterolemia
TARGET      APOB [HSA:338] [KO:K14462] (mRNA)
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             C CARDIOVASCULAR SYSTEM
              C10 LIPID MODIFYING AGENTS
               C10A LIPID MODIFYING AGENTS, PLAIN
                C10AX Other lipid modifying agents
                 C10AX11 Mipomersen
                  D08946  Mipomersen sodium (USAN)
            Target-based classification of drugs [BR:br08310]
             Not elsewhere classified
              Organismal systems
               Digestive system
                APOB
                 D08946  Mipomersen sodium (USAN)
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D08946
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D08946
DBLINKS     CAS: 629167-92-6
            PubChem: 96025629
///
